The combined ratio of estrogen, progesterone, Ki-67, and P53 to predict the recurrence of endometrial cancer

被引:16
作者
Jia, Mingzhu [1 ]
Jiang, Peng [1 ]
Huang, Zhen [1 ]
Hu, Jing [1 ]
Deng, Ying [1 ]
Hu, Zhuoying [1 ]
机构
[1] Chongqing Med Univ, Affiliated Hosp 1, Dept Gynecol, Chongqing 400016, Peoples R China
关键词
combined ratio; cut-off value; endometrial cancer; immunohistochemical markers; recurrence; RECEPTOR; EXPRESSION; SURVIVAL; PATTERNS; PROTEIN; MODELS; IMPACT; WOMEN; ER;
D O I
10.1002/jso.26212
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background and Objectives We aimed to explore the capacity of the combined ratio of biomarkers to predict the recurrence of Stage I-III endometrial cancer (EC). Methods A total of 473 patients were enrolled after screening. The cut-off value of the ratio was calculated by the receiver operating characteristic curve (ROC). The univariate and multivariate Cox regression analysis was used to assess the correlation between the combined ratio and the recurrence of EC. The differences of clinicopathological parameters between the two groups divided based on the threshold were compared. Result The ROC curve showed that 0.92 was the optimal cut-off value of the ratio ([ER + PR]/[P53 + Ki67]). The multivariate analysis demonstrated that only International Federation of Gynecology and Obstetrics stage (p = .031) and the combined ratio (p = .004) were independent risk factors of recurrence. The 3-year recurrence-free survival (RFS) and overall survival of patients in the low-ratio group were 54.1% and 66.8%, respectively; while in the high-ratio group were 94.9% and 97.9%, respectively (p < .001). The 3-year RFS of 194 patients, who did not receive the adjuvant therapy, was 54.7% and 97.2% between two groups (p < .001). Conclusions The optimal cut-off value (0.92) of the combined ratio was demonstrated to be better to predict the recurrence of EC than a single immunohistochemical marker.
引用
收藏
页码:1808 / 1814
页数:7
相关论文
共 29 条
[1]   Prediction models for endometrial cancer for the general population or symptomatic women: A systematic review [J].
Alblas, Maaike ;
Velt, Kimberley B. ;
Pashayan, Nora ;
Widschwendter, Martin ;
Steyerberg, Ewout W. ;
Vergouwe, Yvonne .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2018, 126 :92-99
[2]   Just how accurate are the major risk stratification systems for early-stage endometrial cancer? [J].
Bendifallah, S. ;
Canlorbe, G. ;
Collinet, P. ;
Arsene, E. ;
Huguet, F. ;
Coutant, C. ;
Hudry, D. ;
Graesslin, O. ;
Raimond, E. ;
Touboul, C. ;
Darai, E. ;
Ballester, M. .
BRITISH JOURNAL OF CANCER, 2015, 112 (05) :793-801
[3]   Patterns of recurrence and outcomes in surgically treated women with endometrial cancer according to ESMO-ESGO-ESTRO Consensus Conference risk groups: Results from the FRANCOGYN study Group [J].
Bendifallah, Sofiane ;
Ouldamer, Lobna ;
Lavoue, Vincent ;
Canlorbe, Geoffroy ;
Raimond, Emilie ;
Coutant, Charles ;
Graesslin, Olivier ;
Touboul, Cyril ;
Collinet, Pierre ;
Darai, Emile ;
Ballester, Marcos .
GYNECOLOGIC ONCOLOGY, 2017, 144 (01) :107-112
[4]   The Long-term Prognostic Performance of Ki-67 in Primary Operable Breast Cancer and Evaluation of Its Optimal Cutoff Value [J].
Cho, Uiju ;
Kim, Hee Eun ;
Oh, Woo Jin ;
Yeo, Min-Kyung ;
Song, Byung Joo ;
Lee, Ahwon .
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2016, 24 (03) :159-166
[5]   Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J].
Colombo, N. ;
Preti, E. ;
Landoni, F. ;
Carinelli, S. ;
Colombo, A. ;
Marini, C. ;
Sessa, C. .
ANNALS OF ONCOLOGY, 2013, 24 :33-38
[6]   Impact of Hormone Receptor Status and Ki-67 Expression on Disease-Free Survival in Patients Affected by High-risk Endometrial Cancer [J].
Di Donato, Violante ;
Iacobelli, Valentina ;
Schiavi, Michele Carlo ;
Colagiovanni, Vanessa ;
Pecorella, Irene ;
Palaia, Innocenza ;
Perniola, Giorgia ;
Marchetti, Claudia ;
Musella, Angela ;
Tomao, Federica ;
Monti, Marco ;
Muzii, Ludovico ;
Panici, Pierluigi Benedetti .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 (03) :505-513
[7]   Predictive factors of recurrence following adjuvant vaginal cuff brachytherapy alone for stage I endometrial cancer [J].
Dunn, Emily F. ;
Geye, Heather ;
Platta, Chris S. ;
Gondi, Vinai ;
Rose, Stephen ;
Bradley, Kristin A. ;
Anderson, Bethany M. .
GYNECOLOGIC ONCOLOGY, 2014, 133 (03) :494-498
[8]   Expression of cyclooxygenase-2 (COX-2), receptors for estrogen (ER), and progesterone (PR), p53, ki67, and neu protein in endometrial cancer [J].
Ferrandina, G ;
Ranelletti, FO ;
Gallotta, V ;
Martinelli, E ;
Zannoni, GF ;
Gessi, M ;
Scambia, G .
GYNECOLOGIC ONCOLOGY, 2005, 98 (03) :383-389
[9]   Recurrent early stage endometrial cancer: Patterns of recurrence and results of salvage therapy [J].
Francis, Samual R. ;
Ager, Bryan J. ;
Do, Olivia A. ;
Huang, Yu-Huei Jessica ;
Soisson, Andrew P. ;
Dodson, Mark K. ;
Werner, Theresa L. ;
Sause, William T. ;
Grant, Jonathan D. ;
Gaffney, David K. .
GYNECOLOGIC ONCOLOGY, 2019, 154 (01) :38-44
[10]   Various Clinicopathological Factors Impacting Recurrence in Stage I Endometrial Cancer: A Retrospective Study [J].
Goel, Vipin ;
Ramani, K. ;
Raju, K. V. V. N. ;
Rao, T. Subramanyeshwar ;
Ramchandra, C. H. ;
Gupta, Vikas ;
Fonseca, Daphne .
INDIAN JOURNAL OF GYNECOLOGIC ONCOLOGY, 2019, 17 (03)